



3 April 2023
EMA/111629/2023 Rev. 1

Shortage of Menopur (menotropin) Powder and solvent for solution for injection	
Indication	Menopur is used to treat female and male infertility.
Reason for shortage	In October 2022, the marketing authorisation holder, Ferring, suspended supply of Menopur (all presentations). This was a precautionary measure after the company had been made aware of unapproved changes in the manufacturing process of the active substance of Menopur. As a result supplies of all presentations are constrained in EU Member states. The data available to date do not indicate any immediate safety issue due to the changes in the manufacturing process. Ferring is working with national health authorities in countries where the product is marketed to obtain the necessary approvals and resume supply.
Member States affected¹	Menopur has been or may be temporarily suspended in the following EU member states: Austria, Bulgaria, Croatia, Cyprus, Czechia, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Slovenia, and Spain. Shortages are possible in all other EU Member States where the product continues to be marketed.
Information for healthcare professionals	<ul style="list-style-type: none">• All shipments of Menopur were temporarily suspended which resulted in a shortage of the medicine which may continue through 2023-2024 in some EU countries.• In view of the lack of alternatives in several Member States, Menopur manufactured with unapproved changes may continue to be supplied and used, based on national decision.• In Member States where Menopur is no longer available, alternatives should be used.• A direct healthcare professional communication (DHPC) has been sent to healthcare professionals

¹ This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority.



Shortage of Menopur (menotropin) Powder and solvent for solution for injection

	<p>where needed and is published on the EMA website. Please consult your national shortage register for further advice, including advice on alternatives.</p>
Information for patients	<ul style="list-style-type: none">• All shipments of Menopur were temporarily suspended which resulted in a shortage of the medicine which may continue through 2023-2024 in some EU countries.• In view of the lack of alternatives in several Member States Menopur manufactured with unapproved changes may continue to be supplied and used based on national decision.• In Member States where Menopur is no longer available, alternatives should be used in consultation with the healthcare professional.• Patients who have any questions should speak to their doctor or pharmacist.• Please consult your national shortage register for further advice, including advice on alternatives.
Status	Ongoing